Abstract
Around 90% of congenital cytomegalovirus infected neonates are asymptomatic at birth. Among the infected infants showing no clinical abnormalities, 7 to 15% or over may develop sensorineural hearing loss and only about 50% of these cases are detectable at birth. In 2013, the Neonatal Intensive Care Unit at Maggiore Hospital in Bologna (Italy) introduced a one-page flow chart aimed at identifying neonates with unapparent congenital cytomegalovirus infection by means of selective cytomegalovirus screening of patients who failed to pass a hearing screening test. Since its introduction, 83 infants have been referred to our clinic for sample collection and two cases of congenital cytomegalovirus-related sensorineural hearing loss were diagnosed and treated at the appropriate time.
Keywords:
Cytomegalovirus; congenital infection; sensorineural hearing loss; targeted screening.
MeSH terms
-
Adult
-
Antiviral Agents / therapeutic use
-
Cytomegalovirus / pathogenicity
-
Cytomegalovirus Infections / congenital*
-
Cytomegalovirus Infections / diagnosis*
-
Cytomegalovirus Infections / drug therapy
-
Cytomegalovirus Infections / transmission
-
Early Diagnosis
-
Evoked Potentials, Auditory, Brain Stem / drug effects
-
Female
-
Hearing Loss, Sensorineural / diagnosis*
-
Hearing Loss, Sensorineural / drug therapy
-
Hearing Loss, Sensorineural / physiopathology
-
Hearing Loss, Sensorineural / virology*
-
Humans
-
Infant, Newborn
-
Neonatal Screening / methods*
-
Pregnancy
-
Pregnancy Complications, Infectious / diagnosis*
-
Pregnancy Complications, Infectious / drug therapy
-
Pregnancy Complications, Infectious / physiopathology
-
Pregnancy Complications, Infectious / virology*
-
Recovery of Function
-
Treatment Outcome
-
Valganciclovir / therapeutic use
Substances
-
Antiviral Agents
-
Valganciclovir